TAS-102 (trifluridine and tipiracil, Lonsurf®)

DRUG2 trials

Sponsors

Bayer, Chinese PLA General Hospital

Conditions

Biological TherapyGastric (Stomach) CancerImmunotherapyMetastatic Colorectal Cancer (mCRC)

Phase 2

The Safety and Clinical Efficacy of RAK Cell Therapy in Late-stage Gastric Cancer: A Randomized Controlled Trial

RecruitingNCT07212933

Chinese PLA General HospitalBiological Therapy, Gastric (Stomach) Cancer, Immunotherapy

Start: 2025-07-01End: 2028-06-30Target: 90Updated: 2025-10-08

Unknown Phase

An Observational Study Called STAR-T to Learn More About the Sequential Treatment With Regorafenib and TAS-102 in Adults With Metastatic Colorectal Cancer Under Real World Conditions

CompletedNCT05839951

BayerMetastatic Colorectal Cancer (mCRC)

Start: 2023-04-24End: 2025-04-30Updated: 2025-11-12